COVID-19

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today…

2 years ago
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

REYKJAVIK, Iceland, June 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture…

2 years ago
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEBSirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB

Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB

VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- June 28, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB)…

2 years ago
Ambrx Announces Closing of $75 Million Market Priced Registered OfferingAmbrx Announces Closing of $75 Million Market Priced Registered Offering

Ambrx Announces Closing of $75 Million Market Priced Registered Offering

SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced…

2 years ago
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery PlatformBiora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform

Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform

SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic…

2 years ago
Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility AnalysisPanbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for…

2 years ago
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval DosingCheckpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing

Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing

Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics License Application for cosibelimab under…

2 years ago
Regional Health Properties, Inc. Announces Shareholder Approval of Special Meeting Proposals, Satisfaction of All Conditions to Exchange Offer and Preliminary Results of Exchange OfferRegional Health Properties, Inc. Announces Shareholder Approval of Special Meeting Proposals, Satisfaction of All Conditions to Exchange Offer and Preliminary Results of Exchange Offer

Regional Health Properties, Inc. Announces Shareholder Approval of Special Meeting Proposals, Satisfaction of All Conditions to Exchange Offer and Preliminary Results of Exchange Offer

ATLANTA, GA, June 28, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (NYSE American: RHE) (NYSE American: RHE-PA) (“RHE” or…

2 years ago
Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D DayTaysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

Company views that results of comprehensive data analysis of TSHA-120 and development of disease progression model (DPM) address U.S. Food…

2 years ago